on january 6, 2021, “the 5th annual awards ceremony of hong kong golden stock” was held in shenzhen. alphamab oncology (9966.hk) won the "most valuable medical and pharmaceutical company".
“the 5th annual awards ceremony of hong kong golden stocks" was co-hosted by zhi tong cai jing and hithink royalflush information network co.,ltd, which are well-known domestic hong kong and the u.s. stock information platform. the "most valuable medical and pharmaceutical company" award recognizes hong kong-listed medical and pharmaceutical companies with a healthy corporate governance structure, supreme industry position and well-doing core businesses, capable of offering investors sustainable and stable returns. alphamab oncology is winning of this award demonstrates the industry's attention and recognition of the company's r&d and operation advantages, and it also affirms the company's long-term development potential.
since its establishment, alphamab oncology has been adhering to the original intention of "make cancer manageable and curable diseases", focusing on the development, production and commercialization of innovative anti-tumor biological drugs, and steadily advancing the technology platforms, product pipelines and industrialization bases. rapid growth and continuous innovation have laid a solid foundation. in the past year, the new manufacturing facilities’ phase i production lines have received “drug production license”; 8 ind applications of kn046 and kn026 two bispecific antibody innovative drugs were approved by china and the u.s., 3 clinical data were announced at international academic conferences, more than 10 combination therapies development partnerships were reached, and 3 key clinical trials were initiated... kn046 initiated a phase iii clinical trial for the treatment of non-small cell lung cancer and an internationally registered clinical trial for the treatment of thymic tumors, and obtained the u.s. fda orphan drug designation; the combination therapy of kn026 and kn046 obtained the u.s. fda orphan drug designation with excellent clinical data, and initiated phase ii registration clinical trials to explore new directions for the treatment of her2-positive tumors worldwide. kn035 (envafolimab) bla accepted by the national medical products administration, it is expected to become the world's first subcutaneous pd-(l)1 inhibitor to provide patients with new treatment options. in the future, alphamab oncology will continue to adhere to the dual drive of innovation and internationalization, promote the early listing of innovative drugs. through everyone's efforts, while bringing hope to cancer patients, it will become a great biopharmaceutical company with social responsibility.
about alphamab oncology
alphamab oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.
alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline includes eight tumor monoclonal antibodies and bispecific antibodies and a covid-19 multifunctional antibody. four products have advanced into phase i-iii clinical trials or pre-marketing stage in china, the united states, japan and australia. the bla for kn035(envafolimab) has been accepted by the national medical products administration (nmpa) on december 17.
the company also has state-of-the-art manufacturing capabilities designed and built to meet nmpa and eu/fda’s cgmp standards and a complete quality system which has passed the on-site inspection of an european union qualified person. alphamab oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in china and around the world.
visit http://www.alphamabonc.com for more information.
alphamab oncology forward-looking statements
this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
